interesting times ahead, page-2

Ousia - great post. Well thought out.

PI-88 Trials in Taiwan are a much more 'straightforward' proposition then the Multi Country Phase III undertaking.

Recruitment rates are very difficult to predict in terms of such global Trial. Liver Cancer is a much more prevalent disease in Asia as I understand matters, and therefore recruitment rates are more certain there.

A new dawn for Progen!